Marina Chatziioannou

Marina Chatziioannou

Auto-generated profile, based on publicly available information

Marina Chatziioannou

Research Genetic Cancer Centre Ltd (R.G.C.C. Ltd), Filotas, Florina Greece

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2013 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
PAPanagiotis Apostolou
Panagiotis Apostolou
MTMaria Toloudi
Maria Toloudi
MCMarina Chatziioannou
Marina Chatziioannou
EIEleni Ioannou
Eleni Ioannou
DKDennis R Knocke
Dennis R Knocke
IPIoannis Papasotiriou
Ioannis Papasotiriou
Background: Platinum derivatives are used widely for the treatment of many cancers. However, the toxicity that is observed makes imperative the need for new drugs, or new combinations. Anvirzel™ is an extract which has been demonstrated with experimental data that displays anticancer activity. The aim of the present study is to determine whether the combination of Cisplatin and Anvirzel™ has a synergistic effect against different types of cancer. Materials and methods: To measure the efficacy of treatment with Cisplatin and Anvirzel™, methyl-tetrazolium dye (MTT) chemosensitivity assays were used incorporating established human cancer cell lines. Measurements were performed in triplicates, three times, using different incubation times and different concentrations of the two formulations in combination or on their own. t-test was used for statistical analysis. Results: In the majority of the cell lines tested, lower concentrations of Anvirzel™ induced a synergistic effect when combined with low concentrations of Cisplatin after an incubation period of 48 to 72 h. The combination of Anvirzel™/Cisplatin showed anti-proliferative effects against a wide range of tumours. Conclusion: The results showed that the combination of Anvirzel™ and Cisplatin is more effective than monotherapy, even when administered at low concentrations; thus, undesirable toxic effects can be avoided.

1 August 2014 in Journal of Biological Research-Thessaloniki
Verified
Journal Article
Open access
PDF file
PAPanagiotis Apostolou
Panagiotis Apostolou
MTMaria Toloudi
Maria Toloudi
EKEleni Kourtidou
Eleni Kourtidou
GMGeorgia Mimikakou
Georgia Mimikakou
IVIoanna Vlachou
Ioanna Vlachou
IPIoannis Papasotiriou
Ioannis Papasotiriou
Determination of response to chemotherapy is a major requirement of personalized medicine. Resistance, whether developed or native, critically affects a treatment’s success. Single Cell Gel lectrophoresis - also known as a comet assay - is used to detect DNA damage at the level of individual eukaryotic cells. We assessed the use of comet assays in determining response to chemotherapeutic drugs that are widely used in breast and colon cancer. We treated human breast and colon cancer cell lines with melphalan, cisplatin, mechlorethamine or doxorubicin, as monotherapies. Drug activities varied even in the same cancer types, further demonstrating the heterogeneity of different cancer types. The comet assay technique can provide reliable and quick results with minimum requirements and is applicable to a wide variety of drugs.